The Australian, Imaging, Biomarkers and Lifestyle study of ageing (AIBL) Phase III - Facilitating Early Intervention in Preclinical Alzheimer's disease.

澳大利亚衰老成像、生物标志物和生活方式研究 (AIBL) 第三阶段 - 促进临床前阿尔茨海默病的早期干预。

• 批准号: nhmrc : 1071430
• 负责人: A/Pr Victor Villemagne
• 金额: $ 48.92万
• 依托单位: Institute for Breathing and Sleep
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/australian-imaging-biomarkers-alzheimers-disease/455466
• 关键词: Australian; Imaging; Biomarkers; Lifestyle; study

Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to prevent dementia.

淀粉样蛋白脑部扫描可以在阿尔茨海默病症状首次出现前10-15年发现其发病。淀粉样蛋白的积累被认为是阿尔茨海默病的原因。越早服用旨在减缓淀粉样蛋白积聚或从大脑中清除淀粉样蛋白的药物，就越有可能受益。这项研究将利用澳大利亚AIBL研究的最新发现，开发出最好的方法来发现这些患有脑淀粉样蛋白但没有症状的人，进行早期治疗试验，以预防痴呆症。